Merck's (MRK +0.6%) potential blockbuster insomnia drug suvorexant performs well in two-late...

Merck's (MRK +0.6%) potential blockbuster insomnia drug suvorexant performs well in two-late stage trials, helping patients fall asleep faster and stay in dreamland for longer than a placebo. Suvorexant is designed to minimize morning grogginess, although the major side effects were headaches and...tiredness. Still, Merck intends to file for FDA approval this year.

From other sites
Comments (1)
  • bricius
    , contributor
    Comments (52) | Send Message
    Waking up from a good night sleep with a headache and tiredness? Can anyone call that a good night sleep? May be it's not a bad idea for the pharma industry. A sleeping pill before bedtime then quickly a heavy dose of aspirin upon rising. Better still, Merck and Bayer should join effort to make a combo of suvorexant and delayed-acting aspirin formulation. Good luck Merck! The jury is still out on this one.


    I personally own Merck stocks and am trying to shed some to decrease liability.
    13 Jun 2012, 11:48 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs